Scientists at the University of California, Los Angeles (UCLA) have made a groundbreaking advance in gene-engineered stem cell research, developing a method to modify patients’ blood-forming stem cells to continuously produce cancer-fighting T cells in the body.
The collaborative clinical trial, featuring leading scientists, marks the first human validation of a novel therapeutic strategy: using stem cells as an “internal factory” to generate tumor-targeting immune cells. Published in the latest issue of Nature Communications, the achievement signals a major step forward in enabling the human immune system to regenerate anti-cancer capabilities.
The research team focused on patients with aggressive sarcomas expressing the NY-ESO-1 antigen—a cancer-testis antigen present in 80% of synovial sarcomas. This antigen serves as both a safe therapeutic target and a reliable marker to distinguish tumors from healthy tissue.
By inserting cancer-specific receptors into patients’ own hematopoietic stem cells and transplanting them back via bone marrow infusion, the engineered stem cells continuously produce T cells equipped with antigen receptors. One patient treated with the therapy showed signs of tumor regression, with engineered T cells remaining detectable in the body for months.
This approach addresses a key limitation of traditional immunotherapies—lack of durability—through gene reprogramming. Existing T cell therapies often fail due to cell exhaustion, but stem cells, acting as “immortalized” factories, generate a steady supply of fresh anti-cancer cells. Imaging techniques confirmed that genetically modified stem cells successfully implanted in patients’ bone marrow establish a stable production system.
The team notes that this strategy of building long-term immune responses via hematopoietic stem cells could extend to HIV treatment and resetting immune systems in autoimmune disease patients. Currently, the therapy involves complex steps: stem cell collection, gene editing, and high-dose chemotherapy conditioning. However, technical optimizations may soon position it as a new avenue for preventing cancer recurrence and achieving curative treatment.
Though still in experimental stages and not yet clinically applied, the decade-long research involving over 30 scientists shows broad potential. It offers anew strategic direction for treating solid tumors—where current cell therapies have limited effect, such as lung cancer and sarcomas—and suggests a shift in cancer treatment from single-course interventions to building sustained immune defense systems. By equipping engineered stem cells with tumor-recognizing receptors, the technology provides a continuous “ammunition” supply in the body’s fight against cancer, solving issues of cell exhaustion and reduced efficacy. This 10-year effort may herald a new paradigm in human cancer treatment.
Related topics:
Psilocybin Depression Treatment Benefits Low-Income Adults
Germany Leads EU in Depression Treatment via Psilocybin Access
Acupuncture Aids Depression Treatment via Neuroplastic Signaling
